+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Autoinjectors Market Size, Market Share, Application Analysis, Regional Outlook, Growth Trends, Key Players, Competitive Strategies and Forecasts, 2021 to 2029

  • PDF Icon


  • 100 Pages
  • October 2021
  • Region: Global
  • Acute Market Reports
  • ID: 5615999
With ring trend towards self-administration of drugs, injectable drug delivery solutions such as autoinjectors and pen injectors demonstrate a noteworthy growth potential in the near future. Driven by industry demands, the biopharmaceutical companies worldwide have since introduced a big range of drug injection solutions. In fact, it is also estimated that a significant section of new product entries to the FDA will be drug-device combinations. Among these, autoinjectors is the fastest emerging drug delivery solution that augments patient experience and overcomes compliance concerns by allowing drug administration at home. Apart from patient advantages, reduced number of clinic visits assist in reducing treatment cost for healthcare providers and reduce burden on healthcare personnel. Safety mechanisms and ergonomic designs have helped in addressing dexterity issues faced by patients and avoid the risk of needle-stick injuries.

For the purpose of this report, the global autoinjectors market is studied by device types, therapeutic areas and geography. Based on device types, this market is segmented into manual injection autoinjectors, automated injection autoinjectors, reusable autoinjectors, disposable autoinjectors, variable dose autoinjectors and smart autoinjectors. Anaphylaxis, anticoagulants, autoimmune diseases, emergency medicine, infectious diseases, hematopoietics, hormones, neurology and reproductive health are the chief therapeutic areas where autoinjectors are used. Market size and forecast for the period 2019 to 2029, along with respective CAGRs for the forecast duration 2021 to 2029 are provided in this report for each considered segment.

Based on geographic distribution, the global autoinjectors market is studied for following regional and country level markets:

  • North America
  • United States
  • Canada
  • Europe
  • United Kingdom
  • Germany
  • Rest of Europe
  • Asia Pacific
  • Japan
  • China
  • Rest of Asia Pacific
  • Latin America
  • Middle East and Africa
Market size and forecast, along with respective CAGRs for the considered periods are provided in this section, cumulative to the overall segments.

Along with quantitative information sets, this report includes market assessments in terms of major commercial events mapping, analysis of the major drivers, restraints and opportunities prevalent in the autoinjectors market. In addition, competition analysis tools such as attractive investment proposition and competitive analysis by key market players are also provided in this study for scrutinizing the prevalent competition in the global autoinjectors market. This report concludes with profiles of key companies engaged in development, manufacturing and sale of autoinjectors in the international markets.

The global autoinjectors market is studied for the following device types:

a. Manual Injection Autoinjectors

b. Automated Injection Autoinjectors

c. Reusable Autoinjectors

d. Disposable Autoinjectors

e. Variable Dose Autoinjectors

f. Smart Autoinjectors

The autoinjectors market is technology driven and is dynamic with swift movements and developments being taking place. These devices are gradually overtaking the dominance of conventional self-injection devices. Pediatrics is anticipated to witness fastest adoption of autoinjectors. Manual injectors is the largest segment in the considered device categories. Offered benefits over conventional self-injection systems such as overcoming the risk of needle-stick injury, treatment compliance. Reduced need to visit clinics has led to overall reduction in treatment costs and improved treatment outcomes. Introduction of biologics for drug delivery, better patient adherence, simplified self-administration and growing incidence of chronic diseases are the key drivers facilitating the growth of this market.

Based on therapeutic areas the global autoinjectors market is studied for the following types:

1. Anaphylaxis

2. Hormones

3. Anticoagulants

4. Emergency Medicine

5. Autoimmune Diseases

6. Infectious Diseases

7. Hematopoietics

8. Neurology

9. Reproductive Health

Anaphylaxis is the largest therapeutic area where autoinjectors are widely used. Adrenaline autoinjectors are prescribed to patients with allergies who are at a higher risk of having severe reactions i.e. anaphylaxis. The available autoinjectors across all therapeutic areas are prescription only and require to be prescribed by general practitioners or allergy specialist. Doses for all the considered therapeutic areas are dependent on the stage of condition, age and other such parameter. The use of adrenaline/epinephrine injectors is anticipated to further augment in pediatrics, particularly in the high-income countries, where the incidence of allergies among children is phenomenally high.

Geographically, the autoinjectors market is cumulative to North America, Europe, Asia-Pacific, Middle East and Africa and Latin America.

The detailed regional classification of this market is as follows:
  • North America (U.S. & Canada)
  • Europe (U.K., Germany and Rest of Europe)
  • Asia-Pacific (Japan, China and Rest of Asia-Pacific)
  • Middle East and Africa
  • Latin America
North America is the largest market for autoinjectors. High disease prevalence, swift technological developments, first in line approval for novel products, high healthcare expenditure, favorable reimbursements and quick adoption of new therapeutic solutions are the key factors driving the dominance of North America autoinjectors market. Asia Pacific is anticipated to progress at the fastest growth rate during the forecast period. Factors such as growing awareness in both patients and caregivers, growing healthcare expenditure, rapid development of healthcare infrastructure are the key drivers of Asia Pacific autoinjectors market. Government initiatives, public and private partnerships and augmenting market for reproductive health are some of the other factors supporting the growth of this region.

This product will be delivered within 2 business days.

Table of Contents

Chapter 1 Preface
1.1 Report Description
1.2 Market Segmentation
1.3 Research Methodology
Chapter 2 Executive Summary
2.1 Autoinjectors Market, by Devices, 2020 (USD Mn)
2.2 Autoinjectors Market Share, by Therapeutic Area, 2020 (Value %)
2.3 Autoinjectors Market Share, by Geography, 2020 (Value %)
Chapter 3 Autoinjectors Market: Market Dynamics and Outlook
3.1 Introduction, Facts and Figures
3.2 Drivers
3.3 Challenges
3.4 Opportunities
3.5 Major Market Events Assessment
3.6 Attractive Investment Proposition
3.7 Competitive Analysis: Autoinjectors Market, by Key Market Players
Chapter 4 Global Autoinjectors Market Analysis, by Devices, 2019 - 2029 (USD Mn)
4.1 Preface
4.2 Manual Injection Autoinjectors
4.3 Automated Injection Autoinjectors
4.4 Reusable Autoinjectors
4.5 Disposable Autoinjectors
4.6 Variable Dose Autoinjectors
4.7 Smart Autoinjectors
Chapter 5 Global Autoinjectors Market Analysis, by Therapeutic Area, 2019 - 2029 (USD Mn)
5.1 Preface
5.2 Anaphylaxis
5.3 Anticoagulants
5.4 Autoimmune Diseases
5.5 Emergency Medicine
5.6 Infectious Diseases
5.7 Hematopoietics
5.8 Hormones
5.9 Neurology
5.10 Reproductive Health
Chapter 6 Global Autoinjectors Market Analysis, by Geography, 2019 - 2029 (USD Mn)
6.1 Preface
6.2 North America
6.2.1 United States
6.2.2 Canada
6.3 Europe
6.3.1 United Kingdom
6.3.2 Germany
6.3.3 Rest of Europe
6.4 Asia Pacific
6.4.1 Japan
6.4.2 China
6.4.3 Rest of Asia Pacific
6.5 Middle East and Africa (MEA)
6.6 Latin America
Chapter 7 Company Profiles
7.1 Biogen Idec, Inc.
7.1.1 Business Description
7.1.2 Financial Health and Budget Allocation
7.1.3 Product Positions/Portfolio
7.1.4 News Coverage
7.2 Becton, Dickinson and Company
7.2.1 Business Description
7.2.2 Financial Health and Budget Allocation
7.2.3 Product Positions/Portfolio
7.2.4 News Coverage
7.3 Antares Pharma, Inc.
7.3.1 Business Description
7.3.2 Financial Health and Budget Allocation
7.3.3 Product Positions/Portfolio
7.3.4 News Coverage
7.4 Mylan, Inc.
7.4.1 Business Description
7.4.2 Financial Health and Budget Allocation
7.4.3 Product Positions/Portfolio
7.4.4 News Coverage
7.5 Novartis International AG
7.5.1 Business Description
7.5.2 Financial Health and Budget Allocation
7.5.3 Product Positions/Portfolio
7.5.4 News Coverage
7.6 Unilife Corporation
7.6.1 Business Description
7.6.2 Financial Health and Budget Allocation
7.6.3 Product Positions/Portfolio
7.6.4 News Coverage
7.7 Pfizer, Inc.
7.7.1 Business Description
7.7.2 Financial Health and Budget Allocation
7.7.3 Product Positions/Portfolio
7.7.4 News Coverage
7.8 Scandinavian Health Ltd.
7.8.1 Business Description
7.8.2 Financial Health and Budget Allocation
7.8.3 Product Positions/Portfolio
7.8.4 News Coverage
7.9 Ypsomed Holding AG,
7.9.1 Business Description
7.9.2 Financial Health and Budget Allocation
7.9.3 Product Positions/Portfolio
7.9.4 News Coverage
7.10 Sanofi S. A.
7.10.1 Business Description
7.10.2 Financial Health and Budget Allocation
7.10.3 Product Positions/Portfolio
7.10.4 News Coverage
7.11 Bayer AG
7.11.1 Business Description
7.11.2 Financial Health and Budget Allocation
7.11.3 Product Positions/Portfolio
7.11.4 News Coverage
7.12 Emergent BioSolutions
7.12.1 Business Description
7.12.2 Financial Health and Budget Allocation
7.12.3 Product Positions/Portfolio
7.12.4 News Coverage

Companies Mentioned

  • Biogen Idec Inc.
  • Becton Dickinson and Company
  • Antares Pharma Inc.
  • Mylan Inc.
  • Novartis International AG
  • Unilife Corporation
  • Pfizer Inc.
  • Scandinavian Health Ltd.
  • Ypsomed Holding AG
  • Sanofi S. A.
  • Bayer AG
  • Emergent BioSolutio